BB BIOTECH AG

Q1 2019 13F Holdings

  • Location
    schaffhausen, V8
  • Num holdings

    35

  • Value ($000)

    $3,977,857

  • Date Filed
    05/13/2019
  • Form type
    13F-HR
  • CIK
    0000924223
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2019 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
I
ISI

Ionis Pharmaceuticals Inc.

COM
462222100
$627.04M
16 %

7,725,000

I
INCY

Incyte Corp.

COM
45337C102
$311.36M
8 %

3,620,000

N
NBIX

Neurocrine Biosciences Inc.

COM
64125C109
$296.61M
8 %

3,366,786

V
VRTX

Vertex Pharmaceuticals Inc

COM
92532F100
$239.13M
6 %

1,300,000

S
SAGE

Sage Therapeutics, Inc.

COM
78667J108
$218.73M
6 %

1,375,229

C
CELG

Celgene Corp

COM
151020104
$207.55M
5 %

2,200,000

A
AGIO

Agios Pharmaceuticals, Inc.

COM
00847X104
$200.84M
5 %

2,978,134

A
ALXN

Alexion Pharmaceuticals, Inc.

COM
015351109
$177.68M
5 %

1,314,428

A
ALNY

Alnylam Pharmaceuticals, Inc.

COM
02043Q107
$152.43M
4 %

1,631,089

E
ESPR

Esperion Therapeutics, Inc.

COM
29664W105
$141.45M
4 %

3,522,964

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 35